Development of CAR-T cells specifically targeting cancer stem cell antigen DNAJB8 against solid tumours

Database resources of the national center for biotechnology information

(2021) Eric W Sayers et al.   NUCLEIC ACIDS RESEARCH

Development of an artificial antibody specific for HLA/peptide complex derived from cancer stem-like cell/cancer-initiating cell antigen DNAJB8

(2020) Hiroki Tadano et al.   BRITISH JOURNAL OF CANCER

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy

(2020) Bassel Nazha et al.   Frontiers in Oncology

CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?

(2020) Jessica Wagner et al.   MOLECULAR THERAPY

Target selection for CAR-T therapy

(2019) Jianshu Wei et al.   Journal of Hematology & Oncology

CAR T‐Cell Therapy in Hematologic Malignancies: A Voyage in Progress

(2019) Sarah A. Holstein et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Cellular stress induces cancer stem-like cells through expression of DNAJB8 by activation of heat shock factor 1

(2018) Hiroki Kusumoto et al.   CANCER SCIENCE

The Antigen ASB4 on Cancer Stem Cells Serves as a Target for CTL Immunotherapy of Colorectal Cancer

(2018) Sho Miyamoto et al.   Cancer Immunology Research

Tumor Antigen Escape from CAR T-cell Therapy

(2018) Robbie G. Majzner et al.   Cancer Discovery

Dnajb8, a Member of the Heat Shock Protein 40 Family Has a Role in the Tumor Initiation and Resistance to Docetaxel but Is Dispensable for Stress Response

(2016) Masamichi Yamashita et al.   PLoS One

Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

(2015) Nabil Ahmed et al.   JOURNAL OF CLINICAL ONCOLOGY

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

(2015) D Sommermeyer et al.   LEUKEMIA

CAR T Cells for Solid Tumors

(2014) Sunitha Kakarla et al.   CANCER JOURNAL

Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells

(2014) Rena Morita et al.   CANCER SCIENCE

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

(2014) P. F. Robbins et al.   CLINICAL CANCER RESEARCH

The DNAJB6 and DNAJB8 Protein Chaperones Prevent Intracellular Aggregation of Polyglutamine Peptides

(2013) Judith Gillis et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

HSP DNAJB8 Controls Tumor-Initiating Ability in Renal Cancer Stem-like Cells

(2012) S. Nishizawa et al.   CANCER RESEARCH

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

(2011) C. U. Louis et al.   BLOOD

A DNAJB Chaperone Subfamily with HDAC-Dependent Activities Suppresses Toxic Protein Aggregation

(2010) Jurre Hageman et al.   MOLECULAR CELL

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas

(2009) M Murase et al.   BRITISH JOURNAL OF CANCER